Technology | Artificial Intelligence | February 15, 2018

Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning

Initial launch will include liver and lung artificial intelligence oncology software to empower clinicians to quickly measure and track lesions and nodules in MRI and CT scans

Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning

February 15, 2018 — Arterys Inc. announced its fifth 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Arterys Oncology AI Suite, an artificial intelligence (AI)-based, cloud-based medical imaging software.

The new oncology software complements Arterys’ existing web-based offering, and helps clinicians measure and track tumors or potential cancers, and easily apply radiological standards. The initial deep learning workflows will be for liver magnetic resonance imaging (MRI) and computed tomography (CT) scans, as well as for lung CT scans. With this new technology, radiologists can now easily confirm, evaluate, quantify, and report on the absence or presence of lung nodules and liver lesions along with their key characteristics using a simple web browser. The company plans additional deep learning workflows for solid tumors in other organs.

"The evaluation of primary and metastatic disease in the lung and liver are among the most valuable contributions of radiologists to the care of patients with cancer," said radiologist and Arterys co-founder Albert Hsiao, M.D., Ph.D. "We desperately need more efficient technology to automatically track lung and liver lesions to further improve diagnosis, assess response to treatment, and automate reporting with standardized terminology including Lung-RADS and LI-RADS."

Oncology AI runs on the Arterys MICA (Medical Imaging Cloud AI) platform, which the company said is easier to deploy than on-premise imaging systems and complies with patient data privacy and security requirements in 27 countries. The software uses deep learning to automate the segmentation of lung nodules and liver lesions, with accuracy equal to segmentations performed manually by experienced clinicians. The clinician has the capability to edit these automated segmentations, so they always remain in control.

For more information: www.arterys.com

Related Artificial Intelligence Content

Arterys Receives FDA Clearance for Arterys MICA Web-Based Medical Imaging Analytics Platform

Arterys Partners with GE Healthcare to Launch Viosworks Cardiac Imaging Platform

Arterys Showcases FDA-cleared 4D Flow MRI Software at RSNA 2016

Arterys Cardio DL Cloud MRI Analytics Software Receives FDA Clearance

VIDEO: Editor’s Choice of Most Innovative New Technologies at RSNA 2016

Related Content

Roper Radiologists PA Adapted an Interactive, Dynamic Worklist to Orchestrate and Measure Workflow

Matthew Brady, M.D.

Sponsored Content | Case Study | PACS Accessories | April 18, 2018
Matthew Brady, M.D., a radiologist at Roper Radiologists PA in Charleston, S.C., addresses the often-interwoven topics...
Enhancing Patient Care Inspires Southwest Medical Center to Upgrade to Enterprise Imaging

Assad Zainali, M.D., and Kelly Denton, director of imaging at Southwest Medical Center, review radiology studies with Novarad's Ncompass Enterprise Imaging.

Sponsored Content | Case Study | Enterprise Imaging | April 18, 2018
Southwest Medical Center (SWMC) serves patients from Kansas, Oklahoma, Colorado, New Mexico and Texas. Since seeing its...
MACRA Implications for Payers, Providers and EHR Systems
Feature | Radiology Business | April 18, 2018 | Christopher Emper
For better or worse, the Medicare Access, CHIP Reauthorization Act (MACRA) is expected to disrupt healthcare at every
What It's Going to Take for AI to go Mainstream

Image courtesy of Pixabay

Feature | Artificial Intelligence | April 18, 2018 | Paddy Padmanabhan
No technology concept is going to be more discussed, dissected or debated in healthcare this year than artificial int
This image, taken with Canon's Aquilion One, shows a lung with metastases from bowel cancer.

This image, taken with Canon’s Aquilion One, shows a lung with metastases from bowel cancer. Image courtesy of Canon.

Feature | Lung Cancer | April 18, 2018 | Jeff Zagoudis
In recent years, low-dose computed tomography (CT) screening has emerged as a proven, effective method to detect lung
FDA Clears Siemens' Somatom go.All, go.Top CT Scanners
Technology | Computed Tomography (CT) | April 18, 2018
The U.S. Food and Drug Administration (FDA) has cleared the Somatom go.All and Somatom go.Top computed tomography (CT)...
Carestream's Carbon Nano Tube Portable X-ray System Available for Order
News | Digital Radiography (DR) | April 17, 2018
Carestream Health is taking orders for its new Carestream DRX-Revolution Nano Mobile X-ray System in the United States...
Chest X-ray AI Algorithm Correctly Identifies Lung Disease for Dubai Health Authority
Feature | Artificial Intelligence | April 17, 2018
The Dubai Health Authority (DHA) announced the preliminary results of a chest X-ray artificial intelligence (AI)...
Philips Warns of Cybersecurity Vulnerabilities in IntelliSpace and iSite PACS Products
News | Cybersecurity | April 16, 2018
Philips Healthcare last week issued a proactive advisory warning to its iSite and IntelliSpace picture archiving and...
Canon Medical Systems' Aquilion Precision CT Receives FDA Clearance
Technology | Computed Tomography (CT) | April 13, 2018
April 13, 2018 — Canon Medical Systems USA Inc. this week received U.S.
Overlay Init